Journal profile · Pharmacology, Toxicology and Pharmaceutics-Pharmacology
Diabetes Metabolic Syndrome and Obesity
ISSN 1178-7007 · Dove Medical Press Ltd. · New Zealand
Diabetes Metabolic Syndrome and Obesity: CAS Zone 3 · Medicine (2025 upgraded edition); impact factor 3.8 (journal website); JCR Q2 (journal website); fully open access; APC about USD 4,320; median 96 days to acceptance (114 articles, last 24 months); acceptance rate 10% (journal website); 389 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Diabetes Metabolic Syndrome and Obesity is published by Dove Medical Press Ltd. and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Diabetes, Cardiovascular Risks, and Lipoproteins, Diabetes Treatment and Management and Adipokines, Inflammation, and Metabolic Diseases, together about 30.6% of its articles. Its main subfields are Endocrinology, Diabetes and Metabolism. (generated from OpenAlex topic counts and CAS ranking data)
Editor-in-Chief: Dr Rebecca Baqiyyah Conway Diabetes, Metabolic Syndrome and Obesity is an international, peer-reviewed, open-access journal. The journal is committed to the rapid publication of the latest laboratory and clinical findings that lead to establishing new paradigms in the diagnosis, treatment or prevention of diabetes, metabolic syndrome, or obesity. The journal welcomes original research manuscripts, reviews, expert opinions, and commentaries relating to all aspects of obesity, diabetes, and metabolic syndrome. The journal welcomes submissions to the following sections: Diabetes in Youth Diabetes Pathophysiology and Complications Diabetes Prevention, Care and Management Epidemiology and Public Health Metabolic Disorders and Complications Metabolomics and Lipidomics Nutrition, Exercise and Lifestyle Obesity Psychosocial Aspects of Diabetes, Metabolic Syndrome and Obesity Technology, Treatments and Therapeutics The journal will consider case reports and study protocols only if they make a valuable and original contribution to the literature. When considering submission of a paper utilizing publicly available data, authors should ensure that such studies add significantly to the body of knowledge and that they are validated using the authors’ own data through replication in an original sample. Plant extract studies will only be considered if the active compound has been identified and validated. Updated 16 July 2025
From the journal's Aims & Scope
Research area (LetPub): Pharmacology, Toxicology and Pharmaceutics-Pharmacology
Editor-in-chief Rebecca BaqiyyahPublisher website
Editorial board by country: 7 in mainland China (about 10%); most named United States 21, Mainland China 7, India 6, Iran 6, Saudi Arabia 6 (68 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Diabetes, Cardiovascular Risks, and LipoproteinsMedicine14.3%
- Diabetes Treatment and ManagementMedicine9.4%
- Adipokines, Inflammation, and Metabolic DiseasesMedicine7%
- Diabetes Management and ResearchMedicine5.9%
- Liver Disease Diagnosis and TreatmentMedicine5.4%
- Diabetes Management and EducationMedicine5.2%
- Chronic Kidney Disease and DiabetesMedicine4.8%
- Bariatric Surgery and OutcomesMedicine3.8%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Endocrinology & Metabolism | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Endocrinology & Metabolism | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Endocrinology & Metabolism | Zone 4 |
Top journal: noReview journal: no
JCR / CiteScore quartiles on the journal's website
- JCR Q2 · best quartile · 2025
- CiteScore Q2 · 2025
Publisher-reported: JCR figures are Clarivate's and CiteScore figures Scopus's to confirm; both are a different system from the CAS zones.Publisher website
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor (publisher) 2025
- 3.8Publisher website ·
- 5-year impact factor (publisher)
- 5.3Publisher website ·
- CiteScore 2026-06
- 5.3LetPub ·
- CiteScore (publisher) 2025
- 0.9Publisher website ·
- SJR 2026-06
- 0.89LetPub ·
- SNIP 2026-06
- 0.9LetPub ·
- h-index
- 35LetPub ·
- h-index
- 100OpenAlex ·
- i10-index
- 1,684OpenAlex ·
- 2-year mean citedness
- 3.72OpenAlex ·
- Self-citation rate
- 2.9%LetPub ·
- Share of gold OA articles
- 99.63%LetPub ·
Volume
- Articles per year
- 359LetPub ·
- Downloads per year (publisher)
- 484,478Publisher website ·
Articles by year OpenAlex count · 3,561 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 229 | 229 | 69 |
| 2025 | 389 | 389 | 1,082 |
| 2024 | 426 | 426 | 2,730 |
| 2023 | 373 | 373 | 4,097 |
| 2022 | 350 | 350 | 5,098 |
| 2021 | 449 | 449 | 8,251 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
96 daysMedian, submission to acceptance · P25–P75 72 days – 121 days
- Acceptance to online
- median 27 days (114 articles)
- Submission to online
- median 134 days
- Sample
- 114 articles with submission and acceptance dates (726 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 16 weeksLetPub ·
- Acceptance rate (publisher)
- 10%Publisher website ·
- Desk decision
- 37 daysPublisher website ·
- Submission to publication (journal-reported)
- about 16 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 4,320 | Yes | CC BY, CC BY-NC | |
| OpenAlex | USD 2,836 | — | — | |
| LetPub | USD 3,300 | Yes | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare3 items from the author guidelines
- Reference style
- Vancouver
- First submission
- Free format: the journal's layout is not required
- Graphical abstract
- Optional
Article types accepted2
- case reportAuthors may use these detailed descriptions of different paper types accepted by Dove Medical Press (case reports, reviews, etc) to decide how to label their pa…Length not stated
- reviewAuthors may use these detailed descriptions of different paper types accepted by Dove Medical Press (case reports, reviews, etc) to decide how to label their pa…Length not stated
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Dove Medical Press Ltd.
- Country or region
- New Zealand
- Language
- English
- ISSN
- 1178-7007
- Official links
- Journal homepage ↗DOAJ
- Submission system ↗LetPub
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Diabetes Metabolic Syndrome and Obesity
What CAS zone is Diabetes Metabolic Syndrome and Obesity in?
In the 2025 upgraded edition of the CAS Journal Ranking, Diabetes Metabolic Syndrome and Obesity is in Zone 3 of Medicine, and in Zone 4 of the minor category Endocrinology & Metabolism. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Diabetes Metabolic Syndrome and Obesity?
The journal's website gives an impact factor of 3.8 (2025); this is the journal's own figure, as LetPub lists none for it; CiteScore 5.3, h-index 100.
How long does peer review take at Diabetes Metabolic Syndrome and Obesity?
Based on the dates recorded on 114 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 96 days (interquartile range 72–121 days); authors report an average review time of about 16 weeks; the journal's website gives an acceptance rate of 10%. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What JCR quartile is Diabetes Metabolic Syndrome and Obesity in?
The journal's website gives JCR Q2 (best quartile). JCR quartiles are Clarivate's to confirm and a different system from the CAS zones; in the CAS ranking the journal is in Zone 3 of Medicine.
What are the manuscript requirements of Diabetes Metabolic Syndrome and Obesity?
According to the journal's author guidelines: Reference style: Vancouver; First submission: Free format: the journal's layout is not required; Graphical abstract: Optional. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Diabetes Metabolic Syndrome and Obesity based?
Of the 68 board members whose country the journal's board page names, 7 (about 10%) are in mainland China; the countries named most often are United States (21), Mainland China (7) and India (6). Counted from the institutions listed on the board page; for reference only.
Which databases index Diabetes Metabolic Syndrome and Obesity?
According to LetPub and DOAJ records, Diabetes Metabolic Syndrome and Obesity is indexed in SCIE, Scopus and DOAJ.
Is Diabetes Metabolic Syndrome and Obesity open access, and what is the APC?
Diabetes Metabolic Syndrome and Obesity is a fully open-access journal. APC about USD 4,320.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .